#masld

[getyoungersblog]

the sweet poison. (why your liver is failing).

you avoid fast food. you don't drink beer. you start your morning with a tall glass of orange juice and agave syrup in your oatmeal. you think you are healthy.

why did your doctor just diagnose you with a fatty liver?

(critical warning: MASLD is serious. consult a gastroenterologist. do not rely on internet detoxes).

here is the biology of your metabolism: dietary fat didn't cause this. liquid sugar did. your liver is the ONLY organ that can process fructose. when you flood it with fruit juice, it panics. it triggers de novo lipogenesis—turning that liquid sugar directly into trapped organ fat.

you cannot "detox" your liver. your liver IS the detoxifier.

the biological truth: if you have early-stage steatosis, it is highly reversible! stop the liquid sugar. give your liver cells (hepatocytes) the clinical antioxidants they need to burn off the fat.

i documented the exact biology of this metabolic trap here:

WATCH THE HEPATOLOGY MASTERCLASS

medical disclaimer: this is for educational purposes only. do not self-diagnose.

EXPLORE THE CELLULAR LIVER SUPPORT PROTOCOL

(stop the fake detoxes. support your cells.)

[greenfue]

8 مليار شخص قد يصابون بمرض الكبد الدهني المرتبط بالتمثيل الغذائي بحلول 2050

8 مليار شخص قد يصابون بمرض الكبد الدهني المرتبط بالتمثيل الغذائي بحلول 2050

[idtv-indradhanush]

Even “Once-a-Month” Binge Drinking Can Be Dangerous: New Study Raises Alarm on Liver Health

We often hear people say, “I don’t drink regularly—just once in a while.” But what if that “once in a while” is actually doing more harm than we think?

A recent study from the United States is challenging the idea that occasional heavy drinking is harmless—especially for people already dealing with liver conditions.

What is Binge Drinking?

In simple terms, binge drinking means consuming a large amount of alcohol in a short period:

Women: 4 or more drinks in a day

Men: 5 or more drinks in a day

Even if this happens just once a month, it can still be risky.

What Did the Study Find?

The research analyzed data from over 8,000 individuals between 2017 and 2023, focusing on people with a liver condition called Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

The findings were eye-opening:

People with MASLD who binge drink—even occasionally—have nearly 3 times the higher risk of advanced liver fibrosis.

The risk of serious fibrosis increased by 1.69 times

The risk of advanced fibrosis increased by 2.76 times

In short: the more alcohol consumed in one sitting, the greater the damage to the liver.

Who Is at Higher Risk?

The study also highlighted certain patterns:

Younger individuals and men are more likely to engage in binge drinking

Around 15.9% of MASLD patients reported this habit

This shows that even among people already at risk, occasional heavy drinking is quite common.

Why This Matters

Traditionally, doctors looked at average alcohol consumption to assess risk. But this study shifts the focus:

It’s not just how often you drink—it’s how much you drink at once.

Even infrequent binge drinking can silently accelerate liver damage.

A New Perspective on Liver Health

Researchers suggest that if binge drinking is considered in diagnosis, many more cases could fall under a combined category of metabolic and alcohol-related liver disease.

This could mean:

More people at risk than previously thought

A need for better screening and awareness

The Takeaway

This study sends a clear message:

“Occasional heavy drinking is not safe—especially for those with liver conditions.”

If you or someone you know has liver-related health issues, it may be time to rethink even those “once-in-a-while” drinking habits.

Final Thought

Taking care of your liver isn’t just about cutting down—it’s about understanding your patterns. Sometimes, the habits we consider harmless are the ones quietly causing the most damage.

[masld]

MASLD/MASH Specialist Directory

Access expert-led MASH tools for diagnosis, staging, and management. Developed by GHAPP faculty specifically for APPs in community GI and li

Made primarily for advanced practice providers (APPs), the Director of Specialists for MASLD/MASH provides these professionals the ability to easily obtain contact information for liver specialists to assist with the referral, collaboration, and coordination of patient care. As APPs have the primary responsibility for the initial evaluation and detection of the risk for MASLD/MASH, their role is critical in determining the risk for advanced fibrosis and complex presentations that are of high importance when considering hepatology referrals. The MASLD/MASH Specialist Directory, as part of the MASLD Community Network, provides referrals for the first time, thereby improving multidisciplinary collaboration and continuity of care for patients across the area of metabolic liver diseases.

The Directory is instrumental for advanced practice providers to connect with liver specialists for patient care collaboration and coordination. By being members of the MASLD Community Network, advanced practice providers are able to access a comprehensive system of resources, education, and professional networking.

[ohmarscomeunastro]

Comunque il non alcoholic fatty liver disease è un bastardo. La mia dieta è 90% insalatine di asparago con noci tempeh e carote o pollo e patate al forno o - se siamo cattivi - pasta e fagioli, però vorrei almeno un giorno vivere lo stereotipo di grasso ingrassante e mangiare KFC senza vedere Dio

[masld]

Identifying Hepatic Steatosis: A Guide for APPs

Hepatic steatosis is one of the earliest detectable manifestations of metabolic dysfunction-associated liver disease. Therefore, identifying hepatic steatosis is an important aspect of contemporary metabolic liver care. APPs are often the first point of contact for clinical encounters with patients with obesity, type 2 diabetes, dyslipidemia, and hypertension, and clinical hepatic steatosis. APPs are required to understand the criteria for screening, the imaging techniques and alternative models of clinical best practice in order to ensure the accurate screening and appropriate follow up for clinical hepatic steatosis. APPs are able to identify areas for improvement in their clinical practice related to hepatic steatosis through expert-led education and clinical tools on the MASLD Community Network and improve their clinical practice on the evidence-based management of hepatic steatosis.

Strengthening the Detection of Hepatic Steatosis: APPs Guide is a comprehensive resource for all aspects of detecting hepatic fat, including the appropriate use of imaging, non-invasive risk stratification tools, and clinical best practices. Early detection is imperative to allow APPs to act prior to the onset of associated inflammation and fibrosis, resulting in better long-term outcomes in liver and metabolic health. Using the coaching and educational tools from the MASLD Community Network, advanced practice providers can understand the importance of identifying and streaming patients into organized, proactive metabolic liver care programs.

[masld]

MetALD Assessment and the Role of Advanced Practice Providers

Access expert-led MASH tools for diagnosis, staging, and management. Developed by GHAPP faculty specifically for APPs in community GI and li

As clinicians work through the challenges posed by the overlap of metabolic dysfunction and alcohol-related liver injury, the importance of advanced practice providers (APPs) and MetALD assessment has increased. Metabolic dysfunction-associated alcohol liver disease (MetALD) is a complicated syndromic presentation of metabolic liver disease complicated by alcohol, requiring detailed diagnostic workup, a structured and tailored clinical approach, and an intelligent management plan. In this context, APPs have an unparalleled opportunity to spearhead initiatives that focus on the early identification, risk assessment, clinical judgment, and the overall clinical management of patients with metabolic and alcohol-related co-morbidities. APPs, through evidence-based learning and the collaborative tools available at the MASLD Community Network, can improve their knowledge of MetALD assessment and adopt evidence-based approaches to optimize the clinical management of liver disease at various stages of metabolic liver disease.

At the core of improving early detection, risk assessment, clinical reasoning, and holistic patient care, is MetALD evaluation and the extended role of advanced practice providers. Through the combination of rigid screening, non-invasive fibrosis evaluation, alcohol counseling, metabolic optimization, and multidisciplinary teamwork, advanced practice providers can alleviate the burden of liver-related problems in the long term. With the educational materials and expert collaboration offered through the MetALD Community Network, advanced practice providers have the tools to offer consistent, evidence-based MetALD care, thereby enhancing liver and metabolic health.

[masld]

MASH Clinical Guidelines for APPs

Access expert-led MASH tools for diagnosis, staging, and management. Developed by GHAPP faculty specifically for APPs in community GI and li

As MASH transforms metabolic liver care, MASH Clinical Guidelines for APPs are crucial for integrating structured, evidence-based metabolic liver care. MASH is quickly becoming a leading cause for advanced liver disease, such as cirrhosis, and advanced practice providers (APPs) are the primary clinicians that oversee masses of patients suffering from the metabolic disease of obesity, type 2 diabetes, hypertension, and dyslipidemia. APPs are first contact clinicians for primary and specialty care, which is why the MASH clinical guidelines for APPs are valuable to help clinicians practice their skill sets to the fullest and ensure they Perform early detection and proper staging of MASH, effective management and treatment, monitoring of long-term progression, and apply the best practices of metabolic liver care. APPs now have the needed confidence to span the continuum of care and implement MASH care management, thanks to expert-led education, digital guides, and collaborative practice at the MASLD Community Network.

MASH clinical guidelines for APPs offer the resources to diagnose, stage, create treatment plans, monitor disease, and implement best practices in the metabolic care of the liver. APPs, as frontline clinicians managing patients with multiple complex cardiometabolic conditions, have a critical involvement in the liver-related complication and the overall health burden. Advanced Practice Providers (APPs) through the MASLD Community Network, and structured care pathways, and non-invasive risk stratification, multidisciplinary team (MDT) collaboration, and ongoing education, are equipped to provide confident, consistent, and real MASH impact.